Achilles Therapeutics announces voluntary Nasdaq delisting, SEC deregistration

Written by Emily J. Thompson, Senior Investment Analyst

ACHL%

Updated: Feb 28 2025

0mins

Delisting Notification: Achilles Therapeutics has announced its intention to voluntarily delist its American Depositary Shares from Nasdaq and deregister them with the SEC, coinciding with a planned members' voluntary liquidation set for March 20, 2025.
Future Trading and Reporting: Following the delisting, trading of the ADSs may only occur through private sales or potentially on an over-the-counter market, with no guarantee of continued trading; the company will also suspend its obligation to file periodic reports with the SEC after filing Form 15.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Achilles Therapeutics announces voluntary Nasdaq delisting, SEC deregistration

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Dogecoin Surges 8% to Nearly $0.15 Due to New Senate Crypto Bill Draft

Disney's 17.2 P/E Ratio Suggests Greater Potential than Netflix

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch